Sutent achieves first line EAU approval for kidney cancer
The European Association of Urology (EAU) has recommended Sutent as a first-line treatment for patients with metastatic renal cell carcinoma. Clinical trials have shown that Sutent improves progression-free survival by more than doubling the median PFS compared to interferon-alpha. The new guidelines also highlight Sutent's higher obje...